Literature DB >> 18222493

Chronic haloperidol and clozapine produce different patterns of effects on phosphodiesterase-1B, -4B, and -10A expression in rat striatum.

Daniel Dlaboga1, Hassan Hajjhussein, James M O'Donnell.   

Abstract

Phosphodiesterase-10A (PDE10A), -1B (PDE1B), -4B (PDE4B), and -4A (PDE4A) are important regulators of signal transduction in striatum due to their catalysis of cyclic AMP and cyclic GMP. The typical antipsychotic drug haloperidol and the atypical antipsychotic drug clozapine are thought to regulate cyclic nucleotide signaling in striatum. Since this brain region is essential in mediation of both therapeutic and extrapyramidal side effects, it was of interest to determine whether chronic treatment for 21 days with haloperidol (1 mg/kg) or clozapine (20 mg/kg) affected PDE expression in rat striatum. This was accomplished using SDS-PAGE/immunoblotting and real-time RT-PCR. Both antipsychotic drugs increased PDE10A and did not change PDE4A. By contrast, PDE1B was increased by haloperidol treatment, but not clozapine treatment, while PDE4B was increased by clozapine, but not haloperidol. In all cases, changes in protein expression were accompanied by corresponding changes in mRNA, and only were observed with chronic treatment. Up-regulation of PDEs may represent compensatory responses to haloperidol and clozapine treatments, due to altered cyclic nucleotide signaling, and that different patterns of effects produced by these drugs may be associated with their mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18222493     DOI: 10.1016/j.neuropharm.2007.12.002

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  12 in total

1.  In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Authors:  Hui Liu; Hongjun Jin; Zonghua Luo; Xuyi Yue; Xiang Zhang; Hubert Flores; Yi Su; Joel S Perlmutter; Zhude Tu
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

2.  Phosphodiesterase 4B2 gene is an effector of Toll-like receptor signaling in astrocytes.

Authors:  Elizabeth Borysiewicz; Daniel Fil; Daniel Dlaboga; James M O'Donnell; Gregory W Konat
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

3.  Time-of-Day Dependent Neuronal Injury After Ischemic Stroke: Implication of Circadian Clock Transcriptional Factor Bmal1 and Survival Kinase AKT.

Authors:  Mustafa Caglar Beker; Berrak Caglayan; Esra Yalcin; Ahmet Burak Caglayan; Seyma Turkseven; Busra Gurel; Taha Kelestemur; Elif Sertel; Zafer Sahin; Selim Kutlu; Ulkan Kilic; Ahmet Tarik Baykal; Ertugrul Kilic
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

4.  Phosphodiesterase-1b deletion confers depression-like behavioral resistance separate from stress-related effects in mice.

Authors:  J R Hufgard; M T Williams; C V Vorhees
Journal:  Genes Brain Behav       Date:  2017-06-07       Impact factor: 3.449

5.  Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a.

Authors:  Jillian R Hufgard; Michael T Williams; Matthew R Skelton; Olivera Grubisha; Filipa M Ferreira; Helen Sanger; Mary E Wright; Tracy M Reed-Kessler; Kurt Rasmussen; Ronald S Duman; Charles V Vorhees
Journal:  Psychopharmacology (Berl)       Date:  2017-03-23       Impact factor: 4.530

6.  Antipsychotic induced alteration of growth and proteome of rat neural stem cells.

Authors:  Eakhlas Uddin Ahmed; Selina Ahmed; Wataru Ukai; Izuru Matsumoto; Andrew Kemp; Iain S McGregor; Mohammed Abul Kashem
Journal:  Neurochem Res       Date:  2012-04-18       Impact factor: 3.996

7.  Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanisms.

Authors:  Lianshu Ding; Chong Zhang; Anbrin Masood; Jianxin Li; Jiao Sun; Ahmed Nadeem; Han-Ting Zhang; James M O' Donnell; Ying Xu
Journal:  Behav Brain Res       Date:  2014-03-30       Impact factor: 3.332

8.  Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.

Authors:  M Ayalew; H Le-Niculescu; D F Levey; N Jain; B Changala; S D Patel; E Winiger; A Breier; A Shekhar; R Amdur; D Koller; J I Nurnberger; A Corvin; M Geyer; M T Tsuang; D Salomon; N J Schork; A H Fanous; M C O'Donovan; A B Niculescu
Journal:  Mol Psychiatry       Date:  2012-05-15       Impact factor: 15.992

Review 9.  Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities.

Authors:  Arun Samidurai; Lei Xi; Anindita Das; Audra N Iness; Navin G Vigneshwar; Pin-Lan Li; Dinender K Singla; Sakthivel Muniyan; Surinder K Batra; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2021-04-22       Impact factor: 13.400

10.  Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.

Authors:  S Natesan; S Ashworth; J Nielsen; S-P Tang; C Salinas; S Kealey; J B Lauridsen; T B Stensbøl; R N Gunn; E A Rabiner; S Kapur
Journal:  Transl Psychiatry       Date:  2014-04-01       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.